Applied DNA Sciences, Inc. (APDN)
APDN Stock Price Chart
Explore Applied DNA Sciences, Inc. interactive price chart. Choose custom timeframes to analyze APDN price movements and trends.
APDN Company Profile
Discover essential business fundamentals and corporate details for Applied DNA Sciences, Inc. (APDN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
15 Jul 2003
Employees
46.00
Website
https://www.adnas.comCEO
James A. Hayward Sc.D.
Description
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
APDN Financial Timeline
Browse a chronological timeline of Applied DNA Sciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 11 Feb 2026
Earnings released on 14 Aug 2025
EPS came in at -$34.00 surpassing the estimated -$37.50 by +9.33%, while revenue for the quarter reached $304.39K , missing expectations by -76.14%.
Stock split effective on 2 Jun 2025
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2025
EPS came in at -$230.13 falling short of the estimated -$45.00 by -411.40%, while revenue for the quarter reached $983.37K , missing expectations by -17.01%.
Stock split effective on 14 Mar 2025
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Feb 2025
EPS came in at -$28.00 falling short of the estimated -$16.00 by -75.00%, while revenue for the quarter reached $1.20M , beating expectations by +1.84%.
Earnings released on 17 Dec 2024
EPS came in at -$16.00 surpassing the estimated -$16.50 by +3.03%, while revenue for the quarter reached $813.11K , missing expectations by -9.55%.
Earnings released on 8 Aug 2024
EPS came in at $23.50 surpassing the estimated -$32.00 by +173.44%, while revenue for the quarter reached $797.52K , missing expectations by -11.39%.
Earnings released on 10 May 2024
EPS came in at -$265.50 falling short of the estimated -$230.00 by -15.43%, while revenue for the quarter reached $929.63K , missing expectations by -2.14%.
Stock split effective on 25 Apr 2024
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Feb 2024
EPS came in at -$90.00 surpassing the estimated -$310.00 by +70.97%, while revenue for the quarter reached $891.16K , beating expectations by +14.25%.
Earnings released on 7 Dec 2023
EPS came in at -$260.00 surpassing the estimated -$270.00 by +3.70%, while revenue for the quarter reached $779.74K , missing expectations by -53.60%.
Earnings released on 10 Aug 2023
EPS came in at -$240.00 matching the estimated -$240.00, while revenue for the quarter reached $2.92M , beating expectations by +82.33%.
Earnings released on 11 May 2023
EPS came in at -$200.00 falling short of the estimated -$170.00 by -17.65%, while revenue for the quarter reached $4.41M , beating expectations by +6.98%.
Earnings released on 9 Feb 2023
EPS came in at -$140.00 surpassing the estimated -$330.00 by +57.58%, while revenue for the quarter reached $5.26M , beating expectations by +26.22%.
Earnings released on 14 Dec 2022
EPS came in at -$0.01 surpassing the estimated -$0.26 by +96.15%, while revenue for the quarter reached $3.56M , missing expectations by -13.28%.
Earnings released on 11 Aug 2022
EPS came in at -$330.00 surpassing the estimated -$360.00 by +8.33%, while revenue for the quarter reached $4.30M , beating expectations by +19.31%.
Earnings released on 12 May 2022
EPS came in at -$280.00 surpassing the estimated -$300.00 by +6.67%, while revenue for the quarter reached $6.15M , beating expectations by +36.64%.
Earnings released on 10 Feb 2022
EPS came in at -$630.00 falling short of the estimated -$190.00 by -231.58%, while revenue for the quarter reached $4.17M , beating expectations by +3.21%.
Earnings released on 9 Dec 2021
EPS came in at -$490.00 falling short of the estimated -$320.00 by -53.13%, while revenue for the quarter reached $3.04M , missing expectations by -12.65%.
Earnings released on 12 Aug 2021
EPS came in at -$460.00 falling short of the estimated -$240.00 by -91.67%, while revenue for the quarter reached $1.70M , beating expectations by +43.66%.
Earnings released on 13 May 2021
EPS came in at -$330.00 falling short of the estimated -$180.00 by -83.33%, while revenue for the quarter reached $2.67M , meeting expectations.
Earnings released on 11 Feb 2021
EPS came in at -$620.00 falling short of the estimated -$550.00 by -12.73%, while revenue for the quarter reached $1.62M , beating expectations by +9.09%.
Earnings released on 17 Dec 2020
EPS came in at -$820.00 falling short of the estimated -$590.00 by -38.98%, while revenue for the quarter reached $313.99K .
APDN Stock Performance
Access detailed APDN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.